These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10528675)

  • 21. Autoimmune hemolytic anemia during alpha-interferon treatment in a patient with chronic myelogenous leukemia.
    Stavroyianni N; Stamatopoulos K; Viniou N; Vaiopoulos G; Yataganas X
    Leuk Res; 2001 Dec; 25(12):1097-8. PubMed ID: 11684283
    [No Abstract]   [Full Text] [Related]  

  • 22. Macrovesicular steatosis induced by interferon alfa therapy for chronic myelogenous leukaemia.
    Castéra L; Kalinsky E; Bedossa P; Tertian G; Buffet C
    Liver; 1999 Jun; 19(3):259-60. PubMed ID: 10395047
    [No Abstract]   [Full Text] [Related]  

  • 23. Severe intravascular hemolysis associated with interferon treatment for chronic myeloid leukemia.
    Tuckfield A; Metz J; Grigg A
    Am J Hematol; 1996 Sep; 53(1):52-3. PubMed ID: 8813104
    [No Abstract]   [Full Text] [Related]  

  • 24. [Complete cytogenetic response to interferon-alpha in a patient with chronic myelogenous leukemia undergoing hemodialysis].
    Doi S; Edamura S; Akasaka H; Kawamura M; Arima N; Nasu K
    Rinsho Ketsueki; 2001 Jul; 42(7):549-53. PubMed ID: 11524845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Reversible cardiomyopathy secondary to interferon-alpha in chronic myelogenous leukemia].
    Uehara E; Uesugi T; Tasaka T; Matsuhashi Y; Tamura T; Kuwajima M; Nagai M
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):317-21. PubMed ID: 11865642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired factor VIII inhibitor as presentation of chronic myelogenous leukemia during interferon-alpha therapy.
    Zheng WL; Zhang GS; Shen JK; Pei MF; Peng HL; Xu M
    Thromb Res; 2011 Aug; 128(2):202-3. PubMed ID: 21621826
    [No Abstract]   [Full Text] [Related]  

  • 27. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia.
    Sarasombath P; Sumida K; Kaku DA
    Hawaii Med J; 2002 Mar; 61(3):48, 57. PubMed ID: 11965836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study].
    Du JW; Zhu P; Tian D; Dong ZR; Yang SL; Li SB; Tang YH; Liu H; Cen XN; Zhang Y; Zhu Q; Zhu YL; Yang Y; Wang DX; Wang Z; Cui H; Ma YG; Chen WM; Liu FQ; Ma J; Wang JW; Shen T; Da WM
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1305-9. PubMed ID: 16029627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myasthenia gravis induced by alpha-interferon therapy.
    Pérez A; Perella M; Pastor E; Cano M; Escudero J
    Am J Hematol; 1995 Aug; 49(4):365-6. PubMed ID: 7639296
    [No Abstract]   [Full Text] [Related]  

  • 31. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia.
    Tannir NM; Talpaz M; Ghazal H; Proothi S; Kantarjian HM
    Leuk Lymphoma; 2000 Nov; 39(5-6):647-50. PubMed ID: 11342349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acral sclerosis due to interferon-alpha-2b in chronic myelogenous leukemia.
    Saydam G; Bozkurt D; Sahin F; Yuksel S; Hekimgil M; Omay SB; Buyukkececi F
    Acta Haematol; 2002; 107(1):43-5. PubMed ID: 11818672
    [No Abstract]   [Full Text] [Related]  

  • 33. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.
    Ladoyanni E; Nambi R
    J Drugs Dermatol; 2005; 4(2):221-2. PubMed ID: 15776781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia.
    Benelux CML Study Group
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S19-20. PubMed ID: 8769694
    [No Abstract]   [Full Text] [Related]  

  • 35. Minimal change glomerulonephritis with reversible proteinuria during interferon alpha 2a therapy for chronic myeloid leukemia.
    Rettmar K; Kienast J; van de Loo J
    Am J Hematol; 1995 Aug; 49(4):355-6. PubMed ID: 7639284
    [No Abstract]   [Full Text] [Related]  

  • 36. Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature.
    Colovic M; Jurisic V; Jankovic G; Jovanovic D; Nikolic LJ; Dimitrijevic J
    J Clin Pathol; 2006 Aug; 59(8):879-81. PubMed ID: 16873566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of alpha-interferon in chronic myelogenous leukaemia in Imatinib era.
    Franceschini R; Zoppi F; Garuti A; Gobbi M
    J Exp Clin Cancer Res; 2004 Dec; 23(4):697-8. PubMed ID: 15743042
    [No Abstract]   [Full Text] [Related]  

  • 38. Simultaneous development of SLE-like syndrome and autoimmune thyroiditis following alpha-interferon treatment.
    García-Porrúa C; González-Gay MA; Fernández-Lamelo F; Paz-Carreira JM; Lavilla E; González-López MA
    Clin Exp Rheumatol; 1998; 16(1):107-8. PubMed ID: 9543579
    [No Abstract]   [Full Text] [Related]  

  • 39. Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence?
    Harvey M; Rosenfeld D; Davies D; Hall BM
    Am J Hematol; 1994 Jun; 46(2):152-3. PubMed ID: 8172186
    [No Abstract]   [Full Text] [Related]  

  • 40. "Myorhythmia" slow facial tremor from chronic interferon alpha-2a usage.
    Tan EK; Chan LL; Lo YL
    Neurology; 2003 Nov; 61(9):1302-3. PubMed ID: 14610147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.